Listing 3 - Actual negotiations

Indication:

Mantle cell lymphoma (MCL), relapsed or refractory, in adult patients who have received treatment with a Bruton's tyrosine kinase inhibitor (BTKi)

Indication:

Diabetes Mellitus, Type 1 & 2

Indication:

Solid tumours in adult and pediatric patients that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.

Indication:

Chronic weight management

Indication:

Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen, in adult patients

Indication:

Metastatic Colorectal Cancer

Indication:

Myelodysplastic Syndromes Associated Anemia

Indication:

Hepatic Encephalopathy

Indication:

Beta-Thalassemia Associated Anemia

Indication:

High-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, in adult patients